2HA.F Spero Therapeutics Inc.
- Market cap
- EUR 49.3M
- P/E
- 7.1x
- P/B
- 1.31x
- ROE
- -75.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 2HA.F undervalued?
Graham number2HA.F trades 35.9% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Spero Therapeutics Inc. fundamental analysis
No fundamental analysis for Spero Therapeutics Inc. yet.
Spero Therapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Spero Therapeutics Inc.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It …
Full company profileSpero Therapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Spero Therapeutics Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 3.07M | 48.6M | 96.7M | 27.4M | 59.6M | 516K |
| Operating Income | -88.0M | -30.6M | 26.8M | -72.5M | 7.16M | -34.9M |
| EBITDA | - | -42.9M | 27.2M | -72.5M | 7.16M | -34.9M |
| Net Income | -89.8M | -46.4M | 22.8M | -68.6M | 8.57M | -33.5M |
| EPS | -2.77 | -0.88 | 0.43 | -1.26 | 0.15 | -0.58 |
| Balance Sheet | ||||||
| Total Assets | 171M | 125M | 182M | 111M | 68.9M | 52.8M |
| Total Liabilities | 82.8M | 48.9M | 75.5M | 64.4M | 9.90M | 8.56M |
| Shareholders' Equity | 88.3M | 75.9M | 107M | 46.1M | 59.0M | 44.2M |
| Cash & Short-term Investments | 113M | 109M | 76.3M | 52.9M | 40.3M | 50.8M |
| Cash Flow | ||||||
| Operating Cash Flow | -64.3M | -7.73M | -33.0M | -23.4M | -12.6M | 21.0M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -64.3M | -7.73M | -33.0M | -23.4M | -12.6M | 21.0M |
| Ratios | ||||||
| ROE | -101.7% | -61.1% | 21.3% | -148.7% | 14.5% | -75.8% |
| ROA | -52.5% | -37.2% | 12.5% | -62.0% | 12.4% | -63.5% |
| Net Profit Margin | -2,923.6% | -95.5% | 23.6% | -250.3% | 14.4% | -6,494.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Spero Therapeutics Inc. dividends
Spero Therapeutics Inc. has not paid dividends in the last 5 fiscal years.
Who owns Spero Therapeutics Inc.
- Insiders 22.66%
- Institutions 20.03%
- Public & others 57.31%
- Shares outstanding 58.2M
- Free float 47.1M
Spero Therapeutics Inc. company profile
- Company name
- Spero Therapeutics Inc.
- Ticker
- 2HA.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 25
- Fiscal year end
- December
- Address
- 675 Massachusetts Avenue, Cambridge, MA, United States, 02139
- Phone
- 857 242 1600
- Website
- sperotherapeutics.com
About Spero Therapeutics Inc.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Spero Therapeutics Inc. management
7- Ms. Esther P. RajaveluCEO, President, CFO, Chief Business Officer, Treasurer & Director · born 1979
- Mr. Timothy KeutzerChief Operating Officer · born 1968
- Mr. John RaymondSenior Vice President of Finance & Business Operations
- Dr. Debra Jeske Zack M.D., Ph.D.Chief Medical Officer · born 1957
- Dr. Amy Dix Rock Ph.D.Chief Regulatory & Quality Officer · born 1971
- Dr. Dae Gon Ha Ph.D.Senior Vice President of Corporate Development
- Ms. Sheila FinanSenior VP & Controller